Victor Gurewich
#149,119
Most Influential Person Now
Researcher
Victor Gurewich's AcademicInfluence.com Rankings
Victor Gurewichcomputer-science Degrees
Computer Science
#7718
World Rank
#8123
Historical Rank
Machine Learning
#2950
World Rank
#2987
Historical Rank
Artificial Intelligence
#3243
World Rank
#3291
Historical Rank
Database
#4773
World Rank
#4958
Historical Rank
Download Badge
Computer Science
Victor Gurewich's Degrees
- PhD Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Victor Gurewich Influential?
(Suggest an Edit or Addition)Victor Gurewich's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components (1995) (677)
- Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. (1984) (317)
- Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. (1970) (260)
- Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. (2007) (199)
- Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference. (1980) (188)
- Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. (1983) (183)
- Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. (1986) (180)
- HÆMOSTASIS, FIBRINOLYSIS, AND DEEP-VEIN THROMBOSIS (1973) (149)
- A Critical Evaluation of Thromboangiitis Obliterans (1960) (139)
- High-density lipoproteins and atherosclerosis. (1982) (135)
- Laboratory identification of intravascular coagulation. The serial dilution protamine sulfate test for the detection of fibrin monomer and fibrin degradation products. (1971) (130)
- Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. (1988) (128)
- Activation of plasminogen by single-chain urokinase or by two-chain urokinase--a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). (1987) (125)
- Detection of intravascular coagulation by a serial-dilution protamine sulfate test. (1971) (116)
- α2-PLASMIN INHIBITOR DEFICIENCY (1979) (109)
- Bronchoconstriction in the Presence of Pulmonary Embolism (1963) (84)
- Humoral factors in massive pulmonary embolism: an experimental study. (1968) (78)
- A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. (1986) (78)
- Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK. (1992) (77)
- The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. (2002) (77)
- The Risk of Myocardial Infarction Associated with Antihypertensive Drug Treatment in Persons with Uncomplicated Essential Hypertension (1996) (76)
- Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments. (1987) (76)
- Platelet adherence to thromboemboli in relation to the pathogenesis and treatment of pulmonary embolism. (1966) (74)
- Pulmonary embolism after ligation of the inferior vena cava. (1966) (68)
- A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. (1991) (67)
- High urokinase expression contributes to the angiogenic properties of endothelial cells derived from circulating progenitors (2006) (66)
- Pro‐urokinase and prekallikrein are both associated with platelets (1993) (65)
- Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial. (1995) (64)
- Fibrinogen heterogeneity in human plasma. Electrophoretic demonstration and characterization of two major fibrinogen components. (1974) (59)
- Ximelagatran--promises and concerns. (2005) (58)
- THE AGGREGATION OF HUMAN PLATELETS BY BACTERIAL ENDOTOXIN. (1965) (54)
- Platelet-Bound Prekallikrein Promotes Pro-Urokinase-Induced Clot Lysis: A Mechanism for Targeting the Factor XII Dependent Intrinsic Pathway of Fibrinolysis (1994) (53)
- Letter: Haemostasis, fibrinolysis, and deep-vein thrombosis. (1973) (53)
- The laboratory diagnosis of venous thromboembolic disease by measurement of fibrinogen-fibrin degradation products and fibrin monomer. (1973) (48)
- Thrombospondin forms complexes with single-chain and two-chain forms of urokinase. (1990) (46)
- Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes. (1996) (45)
- Assembly and Activation of the Intrinsic Fibrinolytic Pathway on the Surface of Human Endothelial Cells in Culture (1995) (42)
- The Effect of the Fibrinogen Concentration and the Leukocyte Count on Intravascular Fibrin Deposition from Soluble Fibrin Monomer Complexes (1976) (41)
- Reduction of platelet serotonin and the response to pulmonary emboli. (1971) (41)
- Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator. (1997) (38)
- Urokinase-type Plasminogen Activator-induced Monocyte Adhesion Requires a Carboxyl-terminal Lysine and cAMP-dependent Signal Transduction (*) (1995) (38)
- Transfemoral temporary pacing and deep vein thrombosis. (1980) (37)
- A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. (1996) (37)
- A transitional state of pro-urokinase that has a higher catalytic efficiency against glu-plasminogen than urokinase. (1992) (37)
- Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158). (1988) (37)
- The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs. (1975) (36)
- Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction. (1990) (36)
- Passive Flexion and Femoral Vein Flow: A Study Using a Motorized Foot Mover (1971) (35)
- Some guidelines for heparin therapy of venous thromboembolic disease. (1967) (34)
- A comparative study of precipitation and paracoagulation by protamine sulfate and ethanol gelation tests (1973) (34)
- An efficient system for production of recombinant urokinase-type plasminogen activator. (1997) (34)
- Alpha 2-plasmin inhibitor deficiency. (1979) (33)
- Synergism of Tissue-Type Plasminogen Astivator (t-PA) and Single-Chain Urokinase-Type Plasminogen Activator (scu-PA) on Clot Lysis In Vitro and a Mechanism for this Effect (1987) (33)
- Fibrinogen heterogeneity in cancer, in occlusive vascular disease, and after surgical procedures. (1976) (32)
- Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator. (1987) (31)
- The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator. (1993) (31)
- The Influence of Glycosylation on the Catalytic and Fibrinolytic Properties of Pro-Urokinase (1992) (30)
- Evaluation of antithrombotic properties of suloctidil in comparison with aspirin and dipyridamole. (1976) (30)
- The Sequential, Complementary and Synergistic Activation of Fibrin-bound Plasminogen by Tissue Plasminogen Activator and Pro-urokinase (1989) (30)
- Streptokinase for chronic arterial occlusive disease. (1970) (29)
- A comparison of the rates of clot lysis in a plasma milieu induced by tissue plasminogen activator (t-PA) and rec-pro-urokinase: Evidence that t-PA has a more restricted mode of action (1992) (28)
- Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin. (1994) (27)
- Lipoprotein(a): a kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator. (1993) (27)
- The Organ Distribution of 125I‐Fibrin in the Generalized Shwartzman Reaction and its Relation to Leucocytes (1974) (27)
- Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasminogen activators: Demonstration of a promoting effect by t-PA and by platelets on urokinase (1988) (25)
- Idiopathic pulmonary hemorrhage in pregnancy. Report of a case suggesting early pulmonary hemosiderosis with clinical recovery after steroid therapy. (1959) (25)
- Pathogenesis of venous thrombosis in relation to its prevention by dextran and heparin. (1965) (24)
- Thrombolysis: A Critical First-Line Therapy with an Unfulfilled Potential. (2016) (24)
- Blood coagulation in pregnancy: proconvertin and prothrombin, and the hypercoagulable state. (1956) (23)
- Identification of a Flexible Loop Region (297–313) of Urokinase-type Plasminogen Activator, Which Helps Determine Its Catalytic Activity* (1997) (22)
- Lipoprotein(a) in coronary heart disease. Is it a risk factor after all? (1994) (22)
- Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease. (1977) (22)
- INTRAVASCULAR COAGULATION DURING PREGNANCY AND THE PUERPERIUM (1973) (22)
- Hemostatic effects of uniform, low-dose subcutaneous heparin in surgical patients. (1978) (21)
- A study of the activation of fibrin-bound plasminogen by tissue-type plasminogen activator, single chain urokinase and sequential combinations of the activators (1993) (21)
- Prourokinase Mutant That Induces Highly Effective Clot Lysis Without Interfering With Hemostasis (2002) (21)
- Excercise-induced fibrinolytic activity and its effect on the degradation of fibrinogen, fibrin and fibrin-like precipitates. (1974) (20)
- Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved. (2016) (20)
- Fibrinolysis: an unfinished agenda (2000) (18)
- Health care in the 21st century. (2005) (18)
- The effect of the carboxy-terminal lysine of urokinase on the catalysis of plasminogen activation. (1991) (18)
- Urokinase-type plasminogen activator up-regulates its own expression by endothelial cells and monocytes via the u-PAR pathway. (2001) (17)
- Mutant Prourokinase with Adjunctive C1-Inhibitor Is an Effective and Safer Alternative to tPA in Rat Stroke (2011) (17)
- Highly Effective Fibrinolysis by a Sequential Synergistic Combination of Mini-Dose tPA plus Low-Dose Mutant proUK (2015) (17)
- Clot-selective coronary thrombolysis with lowdose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator☆ (1991) (16)
- Semiquantitative determination of soluble fibrin monomer complexes by chromatography and serial-dilution protamine sulfate test. (1976) (16)
- Evidence for the Expression of Urokinase-type Plasminogen Activator by Human Venous Endothelial Cells In Vivo (1998) (16)
- The Selective Uptake of High Molecular Weight Urokinase-type Plasminogen Activator by Human Platelets (1995) (15)
- Fibrin Degradation Products and Impedance Plethysmography (1980) (15)
- Pro-urokinase: physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action. (1988) (14)
- Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator (2006) (14)
- The value of measuring percent high-density lipoprotein in assessing risk of cardiovascular disease. (1982) (14)
- Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase. (1988) (14)
- Guidelines for the management of anticoagulant therapy. (2008) (14)
- The antithrombotic effect of aspirin and dipyridamole in relation to prostaglandin synthesis. (1983) (13)
- Thrombolysis with Streptokinase in Rabbits Dose Response, Fibrin-clot Specificity and Laboratory Evaluation of Fibrinolytic Effect (1974) (13)
- Catalytic and fibrinolytic properties of recombinant urokinase plasminogen activator from E. coli, mammalian, and yeast cells. (2000) (13)
- Massive intraperitoneal hemorrhage from a ruptured corpus luteum: a rare complication of long-term anticoagulant therapy. (1960) (13)
- Purification Of A New High Mw Single Chain Form Of Urokinase (UK) From Urine (1981) (13)
- Fibrin degradation products and impedance plethysmography. Measurements in the diagnosis of acute deep vein thrombosis. (1980) (12)
- Analysis of the forces which stabilize the active conformation of urokinase-type plasminogen activator. (1998) (12)
- Aortic Pressures during Closed‐Chest Cardiac Massage (1961) (12)
- Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis (2009) (12)
- Demonstration of covalent binding of lipoprotein(a) [Lp(a)] to fibrin and endothelial cells. (1998) (12)
- Activation of intrinsic or extrinsic blood coagulation in experimental venous thrombosis and disseminated intravascular coagulation: pathogenetic differences. (1979) (12)
- Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase. (1989) (12)
- Intra-arterial pro-urokinase in ischemic stroke. (1998) (12)
- Lipids, lipoproteins, fibrinogen and fibrinolytic activity in angiographically assessed coronary heart disease. (1987) (11)
- Epinephrine potentiation of platelet aggregation: its effect on death from experimental pulmonaryeembolism. (1968) (11)
- C1‐inhibitor prevents non‐specific plasminogen activation by a prourokinase mutant without impeding fibrin‐specific fibrinolysis (2007) (11)
- Inactivation of the Intrinsic Activity of Pro-urokinase by Diisopropyl Fluorophosphate Is Reversible (*) (1995) (11)
- Inhibition of intravascular fibrin deposition by dipyridamole in experimental animals. (1975) (11)
- Laboratory Diagnosis of Thrombosis (1977) (11)
- Effects of long-term treatment with suloctidil on blood viscosity, erythrocyte deformability and total fibrinogen plasma levels in diabetic patients. (1979) (10)
- The fate of soluble fibrin monomer in relation to intravascular fibrin formation and degradation in rabbits. (1974) (10)
- The effect of heparin and dipyridamole on the deposition of fibrin-like material in rabbits infused with soluble fibrin monomer or fibrinogen. (1974) (10)
- Fibrin binding and zymogenic properties of single-chain urokinase (pro-urokinase). (1987) (10)
- Case report: low-dose intravenous heparin in the treatment of disseminated intravascular coagulation. (1977) (10)
- Streptokinase in acute pulmonary embolism. (1970) (10)
- The effect of leukopenia versus thrombocytopenia on endotoxin induced intravascular coagulation. (1976) (10)
- Isolation and characterization of an in vivo thrombin-induced anticoagulant activity. (2009) (10)
- Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination (2017) (9)
- The Intrinsic Lysis Concept a (1992) (9)
- Urokinase-type plasminogen activator-induced monocyte adhesion is modulated by kininogen, kallikrein, factor XII, and plasminogen. (1996) (9)
- Managed Care Ethics (1998) (9)
- Peripheral venous scanning with 125 I-tagged fibrinogen. (1972) (9)
- A Pilot Study of Pro-Urokinase in the Treatment of Deep Vein Thrombosis (1994) (9)
- The role of fibrin monomer and an in vivo thrombin-induced-anticoagulant in experimental venous thrombosis. (2009) (8)
- Lower molecular weight fibrinogen and non-clottable fibrinogen derivatives in diabetes mellitus. (1981) (7)
- Thrombin Elaboration in Endotoxin-Induced intravascular Fibrin Deposition (1976) (7)
- Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement (2015) (6)
- Activation of fibrin-bound plasminogen by pro-urokinase and its complementariness with that by tissue plasminogen activator. (1988) (6)
- Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation. (2002) (6)
- The Resistance of Soluble Derivatives of Fibrinogen and the Sensitivity of Its Insoluble Forms to Fibrinolytic Degradation in Blood (1974) (6)
- Differential Detection of Single Chain Urokinase-type Plasminogen Activator and Two Chain Urokinase-type Plasminogen Activator in Human and Monkey Plasma (1992) (6)
- A study of the large heparin requirements in the generalized Shwartzman reaction. (1976) (5)
- Fibrinolysis versus fibrinogenolysis in man: Resistance of fibrinogen to breakdown by fibrinolytic activity induced by venous occlusion (2005) (5)
- Thrombin time prolongation in cirrhosis in relation to enhanced fibrinogen degradation. (1977) (5)
- Substrate inhibition of fibrin-dependent plasminogen activation by tissue-type plasminogen activator. (1993) (5)
- Is coronary thrombolysis associated with side effects that significantly compromise clinical benefits? (1996) (5)
- A fibrin antibody binding to fibronectin induces potent inhibition of angiogenesis (2014) (5)
- Coronary rethrombosis after successful thrombolysis. (1993) (5)
- A critical evaluation of thromboangitis obliterans. The case against Buerger's disease. (1960) (4)
- Platelet Associated u-PA Up-regulates u-PA Synthesis by Endothelial Cells (2002) (4)
- Fibrinolytic Mechanisms of tPA, prouPA, Mutant prouPA and Their Implications for Therapeutic Thrombolysis (2013) (4)
- Non-clottable, protamine sulfate precipitable protein of blood. Studies on its in vitro generation and incorporation into the fibrin clot (1972) (4)
- Letter: The fibrinogenolytic pathway of fibrinogen catabolism: additional comments. (1974) (3)
- Fibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown (2019) (3)
- Urokinase and Single-Chain Urokinase-Type Plasminogen Activator (Pro-urokinase) (2001) (3)
- Treating thromboembolic disease. (1977) (3)
- Primary percutaneous coronary intervention. (2008) (3)
- 114 Comparison of activation of plasminogen by forms of urokinase (UK) with and without the C-terminal lysine of the A-chain (1988) (3)
- 113 Enzymatic and fibrinolytic activities of two lys-158 mutants of pro-urokinase (pro-UK) (1988) (2)
- Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII: comment (2017) (2)
- A MECHANISM FOR THE POTENTIATING EFFECT OF UROKINASE (UK) OR TISSUE PLASMINOGEN ACTIVATOR (t-PA) ON CLOT LYSIS BY PRO-UROKINASE (PRO-UK) (1987) (2)
- The Inhibition of Fibrin Stimulated t-PA-Induced Plasminogen Activation by the A Chain Fragment 149-157 of Urokinase, (1992) (2)
- The pH Dependence of the Binding of Pro-Urokinase to Fibrin/Celite (1990) (2)
- Symptomatic Coronary Artery Disease in a Marathon Runner (1983) (2)
- The vascular war. (1989) (2)
- Binding Of Blood Plasminogen Activator To Fibrinogen, Fibrin Monomer And Fibrin (1981) (2)
- Safety of ximelagatran. Author's reply (2005) (2)
- Fibrinogen, Fibrinogen Heterogeneity and Fibrinolytic Activity in Diabetes Mellitus (1977) (2)
- Fibrin activatable urokinase (FA-UK): a latent form of UK found in urine related to a complex with an inhibitor/fibrin-interacting cofactor. (1988) (2)
- Demonstration of covalent binding of Lp(a) to fibrin and human umbilical vein endothelial cells (HUVEC) (1994) (2)
- FIBRIN-BINDING STUDIES OF PRO-UROKINASE (PRO-UK) USING SOLID PHASE FIBRIN PLATES (1987) (2)
- A comparison of recombinant urokinase with vascular surgery for acute arterial occlusion of the legs. (1998) (2)
- A study of the functional role of the C-terminal lysine on the A-chain of urokinase (UK) in the kinetics of plasminogen activation (1989) (2)
- Structure‐function relationships in thrombin‐activatable fibrinolysis inhibitor: comment (2016) (2)
- Thrombolytic Treatment of Venous Thromboembolism (1977) (2)
- Dextran vs Heparin in Thrombophlebitis (1965) (2)
- Purification Of High Affinity Plasminogen Activator (HAPA) From Blood By Affinity Chromatography On Fibrin-Celite (1981) (2)
- Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group. (1991) (2)
- The Role of Platelets and Leukocytes in Endotoxin-Induced Disseminated Intravascular Coagulation (DIC) (1975) (2)
- Inhibitor to Blood Coagulation Elicited by Thrombin (1975) (1)
- Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial (2022) (1)
- A Mutant Form of Prourokinase That Spares Hemostatic Fibrin (2002) (1)
- Abstract Oral communications I-4: Molecular and structural aspects: Selected abstractDemonstration of covalent binding of lipoprotein(A) [Lp(a)] to fibrin and human umbilical vein endothelial cells (HUVEC) (1994) (1)
- A first‐in‐human study of DS‐1040, an inhibitor of the activated form of thrombin‐activatable fibrinolysis inhibitor, in healthy subjects: comment (2017) (1)
- Safety of Ximelagatran—Reply (2005) (1)
- Letter: The degradation of soluble versus insoluble fibrin in vivo. (1976) (1)
- Using tPA Alone for Fibrinolysis has been A Longstanding Mistake (2021) (1)
- 269 A mechanism for fibrin-dependent plasminogen activation by pro-urokinase (pro-UK) and its complementariness to that of tissue plasminogen activator (t-PA): Relevance to therapetuic and physiological fibrinolysis (1988) (1)
- Preparation of single-stranded phagemid DNA without chromosomal DNA contamination. (1996) (1)
- Exercise-Induced Fibrinolysis – Fact not Fiction (1983) (1)
- The role of urokinase generation during clot lysis by pro-urokinase in a plasma milieu (1993) (1)
- Fibrinolysis: an un®nished agenda (1)
- Biological Properties of Recombinant and of Natural Pro-Urokinase (1985) (1)
- Fibrinolytic therapy with tPA failed because it was based on a flawed concept (2018) (1)
- Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial (2022) (1)
- Fibrinolytic Therapy with tPA Failed Because (2018) (0)
- Assembly and interaction of prekallikrein (PK) and pro-urokinase (pro-UK) on human endothelial cells (ec) (1994) (0)
- THE CONTRIBUTION OF ENDOGENOUS UROKINASE (UK) AND TISSUE PLASMINOGEN ACTIVATOR (t-PA) TO SPONTANEOUS CLOT LYSIS IN PLASMA (1987) (0)
- A New Method for the Determination of Antiplasmin and Antiactivator Activity in Plasma. The Role of these Inhibitors in Controlling the Lysis of Fibrinogen and Fibrin (1979) (0)
- FIBRIN ACTIVATABLE UROKINASE (FA-UK): A LATENT FORM OF UK IN URINE RELATED TO A COMPLEX WITH AN INHIBITOR/FIBRIN-BINDING CO-FACTOR OF UK AND POSSIBLY OF PRO-UK (1987) (0)
- Letter: Inhibitor to blood coagulation elicited by thrombin. (1975) (0)
- What Happened to Fibrinolysis? (2021) (0)
- The Assumption That Fibrinolysis and tPA Can Be Equated is Mistaken (2021) (0)
- Fibrinolysis with tPA Failed Because the Mechanism of Action of both was Misunderstood (2021) (0)
- Heparin Dosage and Clotting Time (1974) (0)
- Thrombolysis: The Current State of The Art and How it can be Improved (2019) (0)
- Pro-urokinase mutant for analysis of occlusive blood clots under recess of wundverschliessenden clots in the treatment of stroke (2004) (0)
- Fibrinolytic Mechanisms of tPA, prouPA, Mutant prouPA and Their Implications for Therapeutic Thrombolysis (2013) (0)
- Fibrinolysis With TPA Alone Is Only One Third As Effective As It Should Be (2020) (0)
- fibrin-binding experiments thrombin-like enzymes: relevance of the findings to the interpretation of Inactivation of single-chain urokinase (pro-urokinase) by thrombin and (2011) (0)
- activator in platelet membranes Evidence for a novel binding protein to urokinase-type plasminogen (2011) (0)
- 2.P.131 Demonstration of covalent binding of lipoprotein(a) [Lp(a)] to fibrin and human umbilical vein endothelial cells (HUVEC) (1997) (0)
- The Use of Percutaneous Coronary Intervention (PCI) for Heart Attack A Critique (2021) (0)
- Thrombolysis, the only Optimally Rapid Reperfusion Treatment (2017) (0)
- 261 Major potentiation by tissue plasmonogen activator (t-PA) and urokinase (UK) of fibrinolysis by LYS-158 mutant pro-urokinase (Pro-UK) (1988) (0)
- Conversion of recombinant single-chain urokinase plasminogen activator (rscu-PA) to the two-chain form (rtcu-PA) in the course of fibrin specific lysis of plasma clots in vitro (1992) (0)
- Formation and Degradation in Rabbits The Fate of Soluble Fibrin Monomer in Relation to Intravascular Fibrin (2011) (0)
- How Fibrinolysis was Defeated by PCI (2021) (0)
- A New Approach to Thrombolysis (2017) (0)
- MANAGED CARE ETHICS. AUTHORS' REPLY (1998) (0)
- Reversible Inhibition of Euglobulin Fibrinolytic Activity in Diabetes Mellitus (DM) (1979) (0)
- Pulmonary thromboembolism. (1973) (0)
- Fibrinogen Heterogeneity, Fibrinolysis and Blood Coagulation in Burned Patients (1977) (0)
- Fibrinolysis has been Misunderstood and as a Result its Therapeutic Potential has Thus far been Wasted (2020) (0)
- skeptical that this observation is drug-related rather than a random event. (2016) (0)
- activity (pro-urokinase) urokinase--a demonstration that single-chain urokinase has a low catalytic Activation of plasminogen by single-chain urokinase or by two-chain (2011) (0)
- Fibrinolysis Versus Fibrinogenolysis: The Specificity of Human Vascular Activator (VA) as Compared to Urokinase (UK) and Streptokinase (SK) (1975) (0)
- tissue plasminogen activator urokinase and promotion of its activity by fibrin fragment E-2 and by The kinetics of plasminogen activation by thrombin-cleaved pro- (2011) (0)
- 797-2 Increased Tissue Factor at Sites of Thrombosis in an Atherosclerotic Animal Model (1995) (0)
- What Fibrinolytic Therapy can Learn from Natural Fibrinolysis: Both Activators are a Requirement (2018) (0)
- Fibrinolysis Using Monotherapy is Inadequate and Risky (2019) (0)
- Thrombolytic therapy for acute myocardial infarction. (1985) (0)
- Mediated by Endogenous Urokinase-Type Plasminogen Activator Thrombin Stimulation of Platelets Induces Plasminogen Activation (2013) (0)
- Results of the pro-urokinase (PRO-UK) and tissue plasminogen activator (t-PA) enhancement of thrombolysis (patent) trial (1994) (0)
- What Fibrinolytic Therapy Can Learn from Endogenous Fibrinolysis; Both Activators Rather Than Only One are Required (2018) (0)
- Plasminogen activator complex of pure pro-urokinase covalently bound to human serum albumin (1990) (0)
- The Use of tPA Alone for Fibrinolysis is based on a Misunderstanding that has Cost Many Lives (2020) (0)
- animals Inhibition of intravascular fibrin deposition by dipyridamole in experimental (2011) (0)
- The broad variability of plasma pro-urokinase (Pro-UK) tolerance and two of its determinants in plasma (1994) (0)
- Thrombolysis with Tissue Plasminogen Activator (Tpa) Alone has been A Longstanding Mistake (2020) (0)
- The Function of tPA in Fibrinolysis is Analogous to the Starter of An Automobile (2021) (0)
- Combination of Single-Chain Urokinase-Type Plasminogen Activator and Recombinant Tissue-Type Plasminogen Activator in Acute Myocardial Infarction (2005) (0)
- The Effect of the Fibrinogen Concentration and White Cell Count on Intravascular Fibrin Deposition (1977) (0)
- Re-Print- The effect of cost and reimbursement on treatment choice (2020) (0)
- Evidence for and possible function of a complex between (latent) PAI-1 and prourokinase (pro-UK) (1994) (0)
- Fibrinolysis and Fibrinolytic Therapy (2018) (0)
- Mutants of pro-urokinase (1994) (0)
- Thrombolytic agents. (1994) (0)
- Proceedings: The role of platelets and leukocytes in endotoxin-induced disseminated intravascular coagulation (DIC). (1975) (0)
- An Experimental study of the Pathogenesis of Venous Thrombosis Versus DIC: The Role of Intrinsic and Extrinsic Coagulation Pathways (1979) (0)
- Letter: Heparin dosage and clotting time. (1974) (0)
- Truth or consequences. (1998) (0)
- THERAPEUTIC FIBRINOLYSIS WITH TPA FAILED BECAUSE TPA’S MECHANISM OF ACTION WAS MISUNDERSTOOD (2020) (0)
- Effective and Safe Fibrinolysis Requires both Plasminogen Activators in a Sequential Combination (2019) (0)
- Lipoprotein(a) Risk in Women and Efficacy of Ascorbate-Reply (1994) (0)
- The tight association of endogenous and exogenous pro-urokinase (PRO-UK) with human platelets (1994) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Victor Gurewich?
Victor Gurewich is affiliated with the following schools:
